Date Title Description PDF
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download

Pages

Date Title Description PDF
07 Jan 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2024 Download
07 Nov 2024 On P&L A correction to the English version of a document is reported. Download
03 Oct 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2024 Download
12 Sep 2024 Other relevant information The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. Download
01 Aug 2024 Other relevant information The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages